Signals, Powered By EquityPandit
Alembic Pharmaceuticals has got the US health regulator’s approval for anti-bacterial Doxycycline capsules.
Alembic Pharmaceuticals said in a BSE filing that “The company has received approval from the United States Food and Drug Administration (USFDA) for its ANDA for Doxycycline capsules USP 75 mg and 100 mg.”
The Abbreviated New Drug Application (ANDA) that has been approved is therapeutically equivalent to a reference listed drug product Monodox capsules, 75 mg and 100 mg of Aqua Pharmaceuticals.
